Cite
HARVARD Citation
Han, G. et al. (n.d.). 595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study. Open forum infectious diseases. p. S401. [Online].